Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Return on Equity (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Return on Equity for 15 consecutive years, with 3.44% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 571.0% to 3.44% in Q3 2025 year-over-year; TTM through Sep 2025 was 3.44%, a 571.0% decrease, with the full-year FY2024 number at 2.84%, up 806.0% from a year prior.
  • Return on Equity was 3.44% for Q3 2025 at Plus Therapeutics, down from 1.29% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 3.82% in Q1 2024 to a low of 20.9% in Q4 2023.
  • A 5-year average of 2.08% and a median of 0.91% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: crashed -1863bps in 2023, then soared 2297bps in 2024.
  • Plus Therapeutics' Return on Equity stood at 0.75% in 2021, then plummeted by -205bps to 2.27% in 2022, then crashed by -820bps to 20.9% in 2023, then skyrocketed by 110bps to 2.07% in 2024, then plummeted by -266bps to 3.44% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Return on Equity are 3.44% (Q3 2025), 1.29% (Q2 2025), and 0.95% (Q1 2025).